#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Jostein Dahle Email
CSO . Nordicnanovector
Oslo,
Locationj*****@nordicnanovector.com
Primary EmailHow to contact Jostein Dahle
Join and see Jostein's contact info for free!j*****@nordicnanovector.com
GROWJO
The Free Company & People Database
Current Roles
Nordicnanovector
Get all of our best features!
About
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.Nordicnanovector Address
Kjelsåsveien 168 BOslo, null
Norway